Researcher for the Antimicrobial Resistance Benchmark
The Antimicrobial Resistance Benchmark team is looking for an experienced researcher to join the team in charge of developing the Antimicrobial Resistance Benchmark, the new tracking tool for evaluating how pharmaceutical companies are taking action to limit antimicrobial resistance (AMR).
12 months (with possibility of renewal).
3 - 5 years.
2,600 EUR – 3,300 EUR per month gross.
Amsterdam, the Netherlands.
Applications will be considered on a rolling basis.
As soon as possible.
The Access to Medicine Foundation is a non-profit organisation based in Amsterdam, the Netherlands. Our mission is to stimulate and guide pharmaceutical companies to do more for the 2 billion people worldwide who cannot access the medicine they need. The core pillar of our work is researching how pharmaceutical companies address the affordability and accessibility of their products in poorer countries. To turn our research into real-world change, we engage with leading organisations, including companies, NGOs and governments.
The Foundation started in 2003 with a single idea: to encourage pharmaceutical companies to compete to be the best at helping the world’s poorest people access the medicine they need. Following the launch of the first-ever Antimicrobial Resistance Benchmark, our work has shed light on where companies are making efforts to ensure antimicrobials are accessible and used wisely– and it shows where further action must now be focused.
Roles and responsibilities
We are looking for a Researcher to join the research team in charge of producing the AMR Benchmark. The main responsibilities include:
- Collecting market intelligence from companies in scope of the Benchmark and updating the R&D pipeline database
- Collecting and analysing data from companies and third parties, including independent publications, reports and other sources
- Enhancing and maintaining the relationship of the AMR team with other stakeholders in the AMR field, under the guidance of the Research Programme Manager
- Upon request, presenting the AMR Benchmark at conferences and external events, including educational seminars
- Collaborating efficiently with other staff members, including those in charge of producing the Access to Medicine Index, coordinating the operations of the Foundation and leading the engagement with companies.
The Researcher will report directly to the Research Programme Manager.
Profile and essential skills
- A medical or pharmacist degree or a Master’s degree in pharmaceutical sciences
- At least 3 years work experience with the pharmaceutical industry
- At least 3 years’ experience conducting analytical research in fields related to life sciences and health and demonstrated experience working with large data sets
- Strong quantitative and qualitative analyses
- Expert use of Excel and statistical packages and proven experience in effective internet searches (ie google alerts) for market intelligence
- Experience in (bio)pharmaceutical pricing, business development, technology transfer, and/or (bio)pharmaceutical or environmental research & development
- Profound knowledge of AMR and infectious diseases; Global Health experience is a plus
- Excellent command of English, both spoken and written (academic and media styles).
- Team player, willing to go the extra mile and with attention to detail
- Available to start asap
- A valid work permit to work in the Netherlands is a plus, EU applicants welcome.
The Access to Medicine Foundation offers benefits that include 25 days’ annual leave (po rata), company pension scheme, holiday allowance and reimbursement of public transport to work (if living beyond 10KM from the office). No reimbursement will be provided for relocation expenses.
About the Antimicrobial Resistance Benchmark
The Antimicrobial Resistance Benchmark (AMR Benchmark) is the first independent analysis of pharmaceutical industry efforts to tackle drug resistance. It compares how a cross-section of the pharmaceutical industry is responding to the threat from drug-resistant infections. It measures the 30 most active players in antimicrobial development and production and includes multinational pharmaceutical companies, biotechnology firms and manufacturers of generic medicines. The main areas tracked are: R&D for new antimicrobials, policies for ensuring antibiotics are manufactured responsibly, and approaches to ensure antimicrobials are accessible and used wisely. Information was gathered and cross-checked from multiple sources.
The Benchmark is being recognised as a new tool for stimulating further action by the pharmaceutical industry on AMR. Jim O’Neill led the 2014 review on AMR commissioned by the UK government. He welcomes the Benchmark for providing the data investors need to compare pharmaceutical companies’ behaviour on the AMR issue, saying “[previously], there were no readily available data by which to make comparisons.” For Dame Sally Davies, the UK’s Chief Scientific Officer, the Benchmark “can help pave the way for a transparent learning culture where best practice is shared, progress celebrated, and gaps where further work is needed are identified.”
How to apply
Interested candidates should send a motivation letter, CV, two reference letters and one writing sample (e.g. thesis, opinion piece, etc.) to Mireille Deen, email@example.com.
Applications will only be reviewed with all supporting documentation.